All articles by Staff Writer
Staff Writer
Sanguina Announces U.S. FDA-Clearance for AnemoCheck Home
AnemoCheck Home is the only FDA-cleared home anemia test with instant results
InfectoGnostics study: Benefits of on-site tests in general practices
Interview with Anni Matthes and Dr. Robby Markwart, Research associates, Institute of General Practice and Family Medicine at the University Hospital Jena
Huawei Accelerates Intelligent Healthcare with the Innovative Digital Medical Technology Solution
During HUAWEI CONNECT 2023, Huawei held the first intelligent healthcare summit themed “Build a Digital Health Community to Accelerate Intelligent Healthcare”. Huawei released the Digital Medical Technology Solution to help the healthcare industry go smart.
Diana Bracco: “Artificial Intelligence will assist radiologists in making increasingly accurate and reliable diagnoses”
Unlocking the AI Revolution – A Symposium on the future of the Healthcare Industry and Diagnostic Imaging in the era of Artificial Intelligence is the title describing the theme of the 2023 edition of Bracco Innovation Day. This event took place at the Human Technopole Auditorium in Milan.
Clario teams up with CellCarta to transform clinical trial sample management for histopathology studies
The fusion of Clario’s innovative endpoint technologies and CellCarta’s sample management expertise offers a single-vendor solution for imaging and histopathology in clinical trials, advancing industry standards.
QIAGEN extends AI capabilities of its NGS interpretation software QCI Interpret to enable clinical exome completeness
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today the expansion of its clinical decision support software, QIAGEN Clinical Insight Interpret (QCI Interpret), to include artificial intelligence (AI)-enhanced coverage of thousands of rare disease genes, advancing its AI-capabilities that have been established for over two decades. The expansion complements the human-certified content curation of QCI Interpret and enables complete bibliographical coverage of the clinical exome.
Jonas Jarvius to step down as CEO of Q-linea during 2024
Jonas Jarvius has informed Q-linea AB:s (publ) (OMX: QLINEA) board of directors that he plans to step down as CEO before summer 2024 to take over as CEO of a US based life science company. Three of the major shareholders of Q-linea (69% of the shares) has informed the Board of Directors of its intention to support Jonas Jarvius as a new board member in 2024.
Revvity Expands Access to Base Editing Technology With Aim to Accelerate Discovery to Cure
Revvity, Inc., (NYSE: RVTY) today unveils its groundbreaking Pin-point™ base editing platform reagents, providing researchers with unparalleled access to implement the advanced gene editing technique in their preclinical laboratories. Base editing represents a pivotal advancement in CRISPR gene editing, providing the capability for complex and safe multi-gene editing, which can result in enhanced functional genomics insights for optimizing drug development, as well as streamlining cell line and cell therapy development and manufacturing. The Pin-point platform is one of the few established base editing technologies currently being employed in clinical settings, positioning it as both a discovery and therapeutic tool.
Hologic and Bayer Announce International Partnership to Deliver Comprehensive Contrast-Enhanced Mammography Package to Breast Imaging Facilities
Partnership Includes Education and Training to Increase Clinician Confidence in the Use of CEM, an Emerging Breast Imaging Modality
QuidelOrtho Receives CLIA Waiver for Sofia® 2 SARS Antigen+ FIA
QuidelOrtho Corporation (Nasdaq: QDEL)(“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it has been granted CLIA Waiver from the U.S. Food and Drug Administration (FDA), applying to its new Sofia® 2 SARS Antigen+ FIA. The Sofia 2 SARS Antigen+ FIA is the first rapid antigen test that detects COVID-19 to be awarded FDA market clearance through the FDA’s De Novo process and is now the first rapid antigen test also to receive CLIA waiver. The test is intended for prescription use only and can be used in CLIA-waived point-of-care settings.